Search Medical Condition
Please enter condition
Please choose location

Lake Success, New York Clinical Trials

A listing of Lake Success, New York clinical trials actively recruiting patient volunteers.

RESULTS

Found (686) clinical trials

Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer

Observational study in the routine clinical practice setting to evaluate the short and long term safety profile of Radium-223 in metastatic castration resistant prostate cancer patients and to evaluate the risk of developing second primary cancers.

Phase N/A

0.0 miles

Learn More »

An Open-Label First-in-Human Study of the Safety Tolerability and Pharmacokinetics of VX-970 in Combination With Cytotoxic Chemotherapy

An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics (PK) of VX-970 in Combination With Cytotoxic Chemotherapy in Subjects With Advanced Solid Tumors

Phase

0.0 miles

Learn More »

A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

This is a multicenter, open-label Phase 2b study of the SINE compound, selinexor. A fixed 60mg dose of selinexor is given orally to patients with relapsed/refractory DLBCL who have no therapeutic options of demonstrated clinical benefit. One hundred thirty patients with relapsed/refractory DLBCL who meet eligibility criteria and have none ...

Phase

0.0 miles

Learn More »

A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

This is a Phase 2, open-label, single arm study to evaluate the safety and efficacy of niraparib in ovarian cancer patients who have received three or four previous chemotherapy regimens. Niraparib is an orally active PARP inhibitor. Niraparib will be administered once daily continuously during a 28-day cycle. Health-related quality ...

Phase

0.0 miles

Learn More »

A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy

A Phase 2 Study to evaluate the Efficacy and Safety of ACP-196 (acalabrutinib) in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy

Phase

0.0 miles

Learn More »

Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to Placebo

To demonstrate that the efficacy of secukinumab 300 mg at Week 16 is superior to placebo in adult patients with active PsA based on the proportion of patients achieving an American College of Rheumatology 20 (ACR20) response.

Phase

0.0 miles

Learn More »

A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus

The purpose is to evaluate the efficacy and safety of three different doses of Dapirolizumab Pegol (DZP) versus placebo in adult subjects with moderately to severely active systemic Lupus Erythematosus receiving stable standard-of-care medications.

Phase

0.0 miles

Learn More »

An Efficacy and Safety Study of CNTO 136 in Patients With Active Lupus Nephritis

This is a multicenter (study conducted at multiple sites), randomized (the study medication is assigned by chance), double-blind (neither investigator nor the patient knows the treatment that the patient receives), placebo-controlled (an inactive substance that is compared with the study medication to test whether the study medication has a real ...

Phase

0.0 miles

Learn More »

Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma

The purpose of Part 1 of this study is to evaluate the safety and tolerability of dalantercept in combination with axitinib in patients with advanced renal cell carcinoma (RCC) to determine the recommended dose level of dalantercept in combination with axitinib for Part 2. The purpose of Part 2 of ...

Phase

0.0 miles

Learn More »

This study is designed to evaluate progression-free survival for ACE-196 vs ibrutinib in previously treated chronic lymphocytic leukemia. Intervention: ACP-196 will be orally administered until disease progression or unacceptable toxicity. Ibrutinib will be orally administered until disease progression or unacceptable toxicity. Study Type: Interventional Study Design: Allocation: Randomized Intervention Model: ...

Phase

0.0 miles

Learn More »